| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
Departments of Obstetrics and Gynecology [B. S., K. H., K. S., S. R., E. K., M. S., W. K., E. L.], Pathology [D. P.], and Statistics and Epidemiology [U. B.], Technische Universität München, Klinikum rechts der Isar, 81675 Munich, Germany; Department of Pathology and Karmanos Cancer Institute, Wayne State University, Detroit, Michigan 48201 [R. F.]; and Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California San Francisco Comprehensive Cancer Center, San Francisco, California 94143-0875 [E. L.]
Proteases are linked to the malignant phenotype of different solid tumors. Therefore, the expression of the matrix metalloproteinase (MMP)-2 and MMP-9 and of the serine protease urokinase-type plasminogen activator (uPA) and its inhibitor plasminogen activator inhibitor type 1 (PAI-1) in the progression of ovarian cancer was investigated. Gelatinolytic activity and protein expression of MMP-2 and MMP-9 were analyzed in tissue extracts of 19 cystadenomas and 18 low malignant potential (LMP) tumors, as well as 41 primary tumors of advanced ovarian cancer stage International Federation of Gynecology and Obstetrics IIIc/IV and their corresponding omentum metastases by quantitative gelatin zymography and Western blot. In the same tissue extracts, antigen levels of uPA and its inhibitor PAI-1 were determined by ELISA. Protein expression of pro-MMP-2 (72 kDa) and pro-MMP-9 (92 kDa as well as antigen levels of uPA and PAI-1 were low in benign ovarian tumors but increased significantly from LMP tumors to advanced ovarian cancers. The highest values of all of the proteolytic factors were detected in omentum metastases. Active MMP-2 enzyme (62 kDa) was detected only in ovarian cancer (66%) and corresponding metastases (93%) but never in benign or LMP tumors. The activation rate of MMP-2 to its active isoform was higher in the metastases. Comparing both proteolytic systems, higher PAI-1 concentrations were consistently found in cancers with high pro-MMP-9 expression. These data indicate that members of the plasminogen activator system, as well as the metalloproteinases MMP-2/9, increase with growing malignant potential of ovarian tumors. These findings are of particular relevance to the development of protease inhibitors as new therapeutic approaches in ovarian cancer.
This article has been cited by other articles:
|
|
 |
|
  M. Satpathy, M. Shao, R. Emerson, D. B. Donner, and D. Matei Tissue Transglutaminase Regulates Matrix Metalloproteinase-2 in Ovarian Cancer by Modulating cAMP-response Element-binding Protein Activity J. Biol. Chem., June 5, 2009; 284(23): 15390 - 15399. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. R. Radjabi, K. Sawada, S. Jagadeeswaran, A. Eichbichler, H. A. Kenny, A. Montag, K. Bruno, and E. Lengyel Thrombin Induces Tumor Invasion through the Induction and Association of Matrix Metalloproteinase-9 and {beta}1-Integrin on the Cell Surface J. Biol. Chem., February 1, 2008; 283(5): 2822 - 2834. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Rao, P. Bhoopathi, C. Chetty, M. Gujrati, and S. S. Lakka MMP-9 Short Interfering RNA Induced Senescence Resulting in Inhibition of Medulloblastoma Growth via p16INK4a and Mitogen-Activated Protein Kinase Pathway Cancer Res., May 15, 2007; 67(10): 4956 - 4964. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Dorn, M. Schmitt, R. Kates, B. Schmalfeldt, M. Kiechle, A. Scorilas, E. P. Diamandis, and N. Harbeck Primary Tumor Levels of Human Tissue Kallikreins Affect Surgical Success and Survival in Ovarian Cancer Patients Clin. Cancer Res., March 15, 2007; 13(6): 1742 - 1748. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. C. Shan, A. Scorilas, D. Katsaros, I. Rigault de la Longrais, M. Massobrio, and E. P. Diamandis Unfavorable Prognostic Value of Human Kallikrein 7 Quantified by ELISA in Ovarian Cancer Cytosols Clin. Chem., October 1, 2006; 52(10): 1879 - 1886. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Y. Zhou and A. S. T. Wong Activation of p70S6K Induces Expression of Matrix Metalloproteinase 9 Associated with Hepatocyte Growth Factor-Mediated Invasion in Human Ovarian Cancer Cells Endocrinology, May 1, 2006; 147(5): 2557 - 2566. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-H. Choi, K.-C. Choi, N. Auersperg, and P. C.K. Leung Gonadotropins Activate Proteolysis and Increase Invasion through Protein Kinase A and Phosphatidylinositol 3-Kinase Pathways in Human Epithelial Ovarian Cancer Cells. Cancer Res., April 1, 2006; 66(7): 3912 - 3920. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. L.G. Sieben, J. Oosting, A. M. Flanagan, J. Prat, G. M.J.M. Roemen, S. M. Kolkman-Uljee, R. van Eijk, C. J. Cornelisse, G. J. Fleuren, and M. van Engeland Differential Gene Expression in Ovarian Tumors Reveals Dusp 4 and Serpina 5 As Key Regulators for Benign Behavior of Serous Borderline Tumors J. Clin. Oncol., October 10, 2005; 23(29): 7257 - 7264. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Agarwal, T. D'Souza, and P. J. Morin Claudin-3 and Claudin-4 Expression in Ovarian Epithelial Cells Enhances Invasion and Is Associated with Increased Matrix Metalloproteinase-2 Activity Cancer Res., August 15, 2005; 65(16): 7378 - 7385. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Marler, S. J. Fishman, S. M. Kilroy, J. Fang, J. Upton, J. B. Mulliken, P. E. Burrows, D. Zurakowski, J. Folkman, and M. A. Moses Increased Expression of Urinary Matrix Metalloproteinases Parallels the Extent and Activity of Vascular Anomalies Pediatrics, July 1, 2005; 116(1): 38 - 45. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Zhou, C. Yu, X. Miao, Y. Wang, W. Tan, T. Sun, X. Zhang, P. Xiong, and D. Lin Functional haplotypes in the promoter of matrix metalloproteinase-2 and lung cancer susceptibility Carcinogenesis, June 1, 2005; 26(6): 1117 - 1121. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Li, X. Ye, C. Mahanivong, D. Bian, J. Chun, and S. Huang Signaling Mechanisms Responsible for Lysophosphatidic Acid-induced Urokinase Plasminogen Activator Expression in Ovarian Cancer Cells J. Biol. Chem., March 18, 2005; 280(11): 10564 - 10571. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Ferrario, C. F. Chantrain, K. von Tiehl, S. Buckley, N. Rucker, D. R. Shalinsky, H. Shimada, Y. A. DeClerck, and C. J. Gomer The Matrix Metalloproteinase Inhibitor Prinomastat Enhances Photodynamic Therapy Responsiveness in a Mouse Tumor Model Cancer Res., April 1, 2004; 64(7): 2328 - 2332. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Scorilas, C. A. Borgono, N. Harbeck, J. Dorn, B. Schmalfeldt, M. Schmitt, and E. P. Diamandis Human Kallikrein 13 Protein in Ovarian Cancer Cytosols: A New Favorable Prognostic Marker J. Clin. Oncol., February 15, 2004; 22(4): 678 - 685. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Yakirevich, E. Sabo, O. Lavie, S. Mazareb, G. C. Spagnoli, and M. B. Resnick Expression of the MAGE-A4 and NY-ESO-1 Cancer-Testis Antigens in Serous Ovarian Neoplasms Clin. Cancer Res., December 15, 2003; 9(17): 6453 - 6460. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. R. Harvey, T. C. Hurd, G. Markus, M. I. Martinick, R. M. Penetrante, D. Tan, P. Venkataraman, N. DeSouza, S. N. J. Sait, D. L. Driscoll, et al. Evaluation of Urinary Plasminogen Activator, Its Receptor, Matrix Metalloproteinase-9, and von Willebrand Factor in Pancreatic Cancer Clin. Cancer Res., October 15, 2003; 9(13): 4935 - 4943. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B.-C. Sheu, H.-C. Lien, H.-N. Ho, H.-H. Lin, S.-N. Chow, S.-C. Huang, and S.-M. Hsu Increased Expression and Activation of Gelatinolytic Matrix Metalloproteinases Is Associated with the Progression and Recurrence of Human Cervical Cancer Cancer Res., October 1, 2003; 63(19): 6537 - 6542. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. M. Yousef, M.-E. Polymeris, L. Grass, A. Soosaipillai, P.-C. Chan, A. Scorilas, C. Borgono, N. Harbeck, B. Schmalfeldt, J. Dorn, et al. Human Kallikrein 5: A Potential Novel Serum Biomarker for Breast and Ovarian Cancer Cancer Res., July 15, 2003; 63(14): 3958 - 3965. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kishi, L. Grass, A. Soosaipillai, A. Scorilas, N. Harbeck, B. Schmalfeldt, J. Dorn, M. Mysliwiec, M. Schmitt, and E. P. Diamandis Human Kallikrein 8, a Novel Biomarker for Ovarian Carcinoma Cancer Res., June 1, 2003; 63(11): 2771 - 2774. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. C. McDonnel, E. A. Van Kirk, D. D. Isaak, and W. J. Murdoch Inhibitory Effects of Progesterone on Plasma Membrane Fluidity and Tumorigenic Potential of Ovarian Epithelial Cancer Cells Experimental Biology and Medicine, March 1, 2003; 228(3): 308 - 314. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Yu, K. Pan, D. Xing, G. Liang, W. Tan, L. Zhang, and D. Lin Correlation between a Single Nucleotide Polymorphism in the Matrix Metalloproteinase-2 Promoter and Risk of Lung Cancer Cancer Res., November 15, 2002; 62(22): 6430 - 6433. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Guo, P. Pakneshan, J. Gladu, A. Slack, M. Szyf, and S. A. Rabbani Regulation of DNA Methylation in Human Breast Cancer. EFFECT ON THE UROKINASE-TYPE PLASMINOGEN ACTIVATOR GENE PRODUCTION AND TUMOR INVASION J. Biol. Chem., October 25, 2002; 277(44): 41571 - 41579. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Kristiansen, C. Denkert, K. Schluns, E. Dahl, C. Pilarsky, and S. Hauptmann CD24 Is Expressed in Ovarian Cancer and Is a New Independent Prognostic Marker of Patient Survival Am. J. Pathol., October 1, 2002; 161(4): 1215 - 1221. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Binder, Th. Hagemann, B. Husen, M. Schulz, and A. Einspanier Relaxin enhances in-vitro invasiveness of breast cancer cell lines by up-regulation of matrix metalloproteases Mol. Hum. Reprod., September 1, 2002; 8(9): 789 - 796. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
